collectively referred to as the "Transaction"). The Transaction constituted a reverse takeover of the Company by FTP under applicable securities laws. FTP became a.
FDA advisory committee determines phase 3 study of lecanemab, a monoclonal antibody directed against amyloid beta confirms the drug s clinical benefit for patients with Alzheimer s disease.